Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Hummingbird Diagnostics GmbH. (10/9/18). "Press Release: Jörg Debatin to Chair the Supervisory Board of Hummingbird Diagnostics GmbH". Heidelberg & Boston, MA.

Organisations Organisation Hummingbird Diagnostics GmbH
  Organisation 2 GE Healthcare
  Group General Electric (Group)
Products Product diagnostics (medical/biological)
  Product 2 microRNA (miRNA) technology
Persons Person Debatin, Jörg F. (General Electric 201408– CP + CTO at GE Healthcare before Amedes + Univ Medical Center Eppendorf)
  Person 2 Kohlhaas, Jochen (Comprehensive Biomarker Center 201112– Managing Director before febit)
     


International healthcare leader strengthens miRNA experts


Hummingbird Diagnostics GmbH today announced that Prof. Dr. med. Jörg Debatin is appointed Chairman of the Supervisory Board with immediate effect.

The former Vice President and Chief Technology Officer of GE Healthcare and CEO of Amedes AG directed the University Hospital Hamburg-Eppendorf for 8 years as its Medical Director and CEO.

He started his professional career as a diagnostic radiologist at the University Hospitals of Duke, Stanford and Zürich (Switzerland). In 1999, he was appointed Professor of Diagnostic Radiology at the University of Essen. Debatin has studied medicine at the University of Heidelberg and holds an Executive MBA from the University of St. Gallen.

As a renowned international healthcare leader, he has extensive academic, clinical, and entrepreneurial experience in the fields of medical diagnostics and disease management as well as the implementation of innovative technologies.

Thus, Prof. Debatin ideally augments the wide-ranging expertise of the Hummingbird Supervisory Board. Leading scientists, industrial managers and experienced investors support the company in expanding its portfolio of products and applications.

“At Hummingbird, we are delighted to have Jörg Debatin on board, a globally renowned healthcare leader,” says Jochen Kohlhaas, CEO of Hummingbird Diagnostics GmbH. „His longstanding experience is invaluable for our future corporate development. “

“I am very happy to support Hummingbird Diagnostics in navigating upcoming challenges,“ Prof. Debatin remarks. “Using blood-based biomarkers for measuring the immune responses to disease holds immense promise for screening, symptom-based diagnostics, disease-specific prognosis and monitoring of patient-centered therapies.”


Hummingbird Diagnostics GmbH

Hummingbird Diagnostics GmbH develops patient-friendly diagnostics for early disease detection based on miRNA biomarkers from blood, in particular for malignant tumors. In addition, the company is working on life-accompanying tests for healthy aging.


For further information please contact:

Hummingbird Diagnostics GmbH
Im Neuenheimer Feld 583
D-69120 Heidelberg
phone +49 (0)6221 91433-10
fax +49 (0)6221 91433-12
info@hb-dx.com
www.hummingbird-diagnostics.com

   
Record changed: 2018-10-15

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Hummingbird Diagnostics GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top